INFLECTRA
PeakmAbBLAINJECTIONINJECTABLE
Approved
Apr 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
5/8 — Partial
INFLECTRA by Celltrion is tnfα by binding with high affinity to the soluble and transmembrane forms of tnfα and inhibit binding of tnfα with its receptors. First approved in 2016.
Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INFLECTRA (infliximab-dyyb) is a biosimilar monoclonal antibody that blocks tumor necrosis factor (TNF), a key inflammatory cytokine. It is approved for multiple immune-mediated inflammatory diseases including rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriasis, and psoriatic arthritis. The drug works by binding to TNF receptors, reducing inflammatory signaling and clinical symptoms.
$0.032BPart D
PeakPeak-stage biosimilar with $32M Part D spending generating modest commercial activity; team size likely stable with focus on market defense against competitor biosimilars.
Mechanism of Action
TNFα by binding with high affinity to the soluble and transmembrane forms of TNFα and inhibit binding of TNFα with its receptors. Infliximab products do not neutralize TNFβ (lymphotoxin-α), a related cytokine that utilizes the same receptors as TNFα. Biological activities attributed to TNFα…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on INFLECTRA at Celltrion? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.